Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Endonovo Therapeutics Inc (OTCMKTS:ENDV) Stock In Focus After Recent Development

Stocks may often trade in a range but if there is any material news about the company then investors could do well to check it out. After all, the stock may break out owing to that eventually.

Market Stats

On Wednesday, ENDV stock ended flat at $0.0170 with more than 13k shares, compared to its average volume of 124K shares. The stock moved within a range of $0.0170 – 0.0179 after opening trading at $0.0179.        

Key Details

The Endonovo Therapeutics Inc (OTCMKTS:ENDV) stock was trading within a range yesterday but the medical devices development company was also in the news. The company announced yesterday that it had submitted a Regulation A+ financing for the purposes of expanding its operations. In order to accomplish that, the company decided to retain the services of Dalmore Group.

Dalmore Group is one of the oldest operators in the broker-dealer industry and specialises in providing the compliance as well as operational services for completing the Regulation A+ filing. The Regulation A+ offering is going to be used by Endonovo Therapeutics for raising fresh capital.

The company is going to use the proceeds from the offering for the purposes of repaying the senior secured notes, spending towards research and development and also for fulfilling working capital needs. It may now be a good idea for investors to consider adding the stock to their watch lists and see if there is any significant move in the coming days.

Key Quote

Etan Butler, Chairman of Dalmore Group states, “having onboarded over 175 Reg A+ issuers since 2019, we are now seeing a rapid increase of OTC companies utilizing the Reg A+ exemption as a means to raise capital for their businesses”.

Additionally, Mr. Butler explains “Dalmore has onboarded over 20 publicly traded Reg A+ issuers. With our expanding list of institutional investors seeking to invest in OTC companies through Reg A+, and our relationships with syndicate broker dealers and their retail investor bases, Dalmore is seeing a trend of OTC companies choosing the Reg A+ path to finance their capital raising needs.” As stated in Dalmore Group’s February 8, 2022 press release.

Traders Corner

ENDV stock is trading below the 20-Day and 50-Day Moving averages of $0.0187 and $0.0186 respectively. The stock is trading in neutral zone with the RSI at 44. 

Published by Pete Matthews

Pete attended the University of Colorado and still calls the centennial state home. He chases trout in the summer and snowboards in the winter. He is fascinated with the markets and has a strong interest in nanocap stocks and crypto currency.

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
*By submitting your information you agree to the terms of our Privacy Policy. You will receive the DRP Journal newsletter, and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.